Biologicals in rheumatoid arthritis: Current and future

RMD Open

Volumn 1, Issue 1, 2015, Pages

  Avci, Ali Berkant ^a   Feist, Eugen ^b   Burmester, Gerd R ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018193256     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2015-000127     Document Type: Review

References (82)

1. Weinblatt ME, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford) 2012;51:2204-14.
2. Combe B, Dasgupta B, Louw I, et al. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis 2014;73:1477-86.
3. Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014;73:803-9.
4. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64:2824-35.
5. Van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379:1712-20.
6. O'Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369:307-18.
7. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2015;74:1037-44.
8. Jobanputra P, Maggs F, Deeming A, et al. A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ open 2012;2:e001395.
9. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86-94.
10. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
11. Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63:2854-64.
12. Weinblatt ME, Bingham CO III, Mendelsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 2013;72:381-9.
13. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69-74.
14. Allaart CF, Lems WF, Huizinga TW. The BeSt way of withdrawing biologic agents. Clin Exp Rheumatol 2013;31(4 Suppl 78):S14-18.
15. Emery P, Hammoudeh M, FitzGerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 2014;371:1781-92.
16. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383:321-32.
17. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50.
18. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69:1286-91.
19. Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74:389-95.
20. Smolen JS, Emery P, Ferraccioli GF, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 2015;74:843-50.
21. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
22. Huizinga TW, Conaghan PG, Martin-Mola E, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 2015;74:35-43.
23. Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 2015;74:19-26.
24. Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 2015. Published Online First 6 Feb 2015. doi:10.1136/annrheumdis-2014- 206439.
25. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20.
26. Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 2014;73:1626-34.
27. Genovese M, Fleischmann RM, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study. Arthritis Rheum 2015;67:1424-37.
28. Fleischmann R, Decktor DL, Fan C, et al. Comparable efficacy with sarilumab plus methotrexate in biologic-experienced and biologic-naïve patients with moderate-to-severe rheumatoid arthritis from a phase 3, randomized, double-blind, placebo-controlled, international study. [2823]. ACR2014.
29. Kavanaugh A, Decktor DL, Fan C, et al. A profile of the efficacy of sarilumab plus methotrexate in rheumatoid arthritis patients: results of a 52-week, phase 3, randomized, double-blind, placebo-controlled, international study. [2824]. ACR2014.
30. Huizinga TW, Kivitz AJ, Rell-Bakalarska M, et al. Sarilumab for the treatment of moderate-to-severe rheumatoid arthritis: results of a phase 2, randomized, double-blind, placebo-controlled, international study. [OP0023]. EULAR2012.
31. Smolen JS, Weinblatt ME, Sheng S, et al. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2014;73:1616-25.
32. Genovese MC, Fleischmann R, Furst D, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase IIb study. Ann Rheum Dis 2014;73:1607-15.
33. Mease P, Strand V, Shalamberidze L, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012;71:1183-9.
34. Weinblatt M, Mease P, Mysler E, et al. A phase IIb study of the efficacy and safety of subcutaneous clazakizumab (anti-IL-6 monoclonal antibody) with or without methotrexate in adults with moderate-to-severe active rheumatoid arthritis and an inadequate response to methotrexate. [SAT0244]. EULAR2014.
35. Holz JB, Sargentini-Maier L, De Bruyn S, et al. Twenty-four weeks of treatment with a novel anti-IL-6 receptor Nanobody® (ALX-0061) resulted in 84% ACR20 improvement and 58% DAS28 remission in a phase I/II study in RA. [OP0043]. EULAR2013.
36. Rigby W, Tony HP, Oelke K, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012;64:350-9.
37. Stohl W, Gomez-Reino J, Olech E, et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis 2012;71:1289-96.
38. Tak PP, Mease PJ, Genovese MC, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012;64:360-70.
39. Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebocontrolled, phase I/II study. Arthritis Rheum 2010;62:2227-38.
40. Taylor PC, Quattrocchi E, Mallett S, et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2011;70:2119-25.
41. Kurrasch R, Brown JC, Chu M, et al. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. J Rheumatol 2013;40:1089-96.
42. Genovese MC, Bojin S, Biagini IM, et al. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biological therapy: a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2013;65:880-9.
43. Genovese MC, Fleischmann RM, Greenwald M, et al. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis 2013;72:1461-8.
44. Genovese MC, Lee E, Satterwhite J, et al. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2013;72:1453-60.
45. Genovese MC, Silverman GJ, Emery P, et al. Efficacy and safety of subcutaneous administration of tabalumab, an anti-B cell activating factor monoclonal antibody, in rheumatoid arthritis: results from a phase 3 multicenter, randomized, double-blind study. [1732]. ACR2013.
46. Smolen JS, Weinblatt ME, van der Heijde D, et al. Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicenter, randomised, double-blind study. Ann Rheum Dis 2015;74:1567-70.
47. Schiff M, Combe B, Dörner T, et al. Efficacy and safety of tabalumab, an anti-B cell activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to TNF-alpha inhibitors: results from a phase 3 multicenter, randomized, double-blind study. [AB0438]. EULAR2014.
48. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62:929-39.
49. Genovese MC, Greenwald M, Cho CS, et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheum 2014;66:1693-704.
50. Genovese MC, Durez P, Richards HB, et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 2014;41:414-21.
51. Martin DA, Churchill M, Flores-Suarez L, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013;15:R164.
52. Pavelka K, Chon Y, Newmark R, et al. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol 2015;42:912-19.
53. Burmester GR, Feist E, Sleeman MA, et al. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 2011;70:1542-9.
54. Burmester GR, Weinblatt ME, McInnes IB, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2013;72:1445-52.
55. Burmester G, McInnes IB, Kremer JM, et al. Efficacy and safety/ tolerability of mavrilimumab, a human GM-CSFRa monoclonal antibody in patients with rheumatoid arthritis. [2821]. ACR2014.
56. Behrens F, Tak PP, Østergaard M, et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 2015;74:1058-64.
57. A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 administered under the skin of patients with active rheumatoid arthritis, despite existing methotrexate therapy. ClinicalTrials.gov NCT01645280 (accessed 19 Apr 2015).
58. Rasmussen TK, Andersen T, Hvid M, et al. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol 2010;37:2014-20.
59. First-in-Man Trial of NNC114-0005 in healthy subjects and subjects with rheumatoid arthritis. ClinicalTrials.gov NCT01208506; (accessed 19 Apr 2015).
60. Safety and tolerability of NNC0114-0006 at increasing dose levels in subjects with rheumatoid arthritis. ClinicalTrials.gov NCT01565408; (accessed 19 Apr 2015).
61. A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of NNC0114-0006 in subjects with active rheumatoid arthritis. ClinicalTrials.gov NCT01647451; (accessed 19 Apr 2015).
62. Hsu YH, Li HH, Hsieh MY, et al. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum 2006;54:2722-33.
63. Kotbi NA, Jensen L, Graff LB. NNC0109-0012 (anti-IL-20 mAb), well tolerated in healthy subjects and patients with rheumatoid arthritis. [FRI0196]. EULAR2012.
64. Leszczynski P, Eshof MK, Stegmann HVB, et al. NNC0109-0012 (anti-IL-20 mAb), well tolerated in patients with rheumatoid arthritis. [FRI0197]. EULAR2012.
65. Senolt L, Göthberg M, Valencia X, et al. Efficacy and safety of NNC0109-0012 (anti-IL-20 mAb) in patients with rheumatoid arthritis: results from a phase 2a trial. [LB0004]. EULAR2012.
66. Senolt L, Hansen BB, Strandberg-Larsen M, et al. Improvements in patient-reported physical function, pain and global disease activity in patients with rheumatoid arthritis after treatment with NNC0109- 0012 (anti-IL-20 mAb) in a phase 2a trial. [SAT0112]. EULAR2013.
67. A trial of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to methotrexate. ClinicalTrials.gov NCT01636843; (accessed 19 Apr 2015).
68. A trial of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to anti-TNFa biologics. ClinicalTrials.gov NCT01636817; (accessed 19 Apr 2015).
69. A trial investigating the mechanism of action of NNC0109-0012 (Anti-IL-20 mAb) through synovial biopsies in subjects with rheumatoid arthritis and an inadequate response to methotrexate. ClinicalTrials.gov NCT02097264; (accessed 19 Apr 2015).
70. Hsu B, Chiou CF, Sheng S, et al. Sirukumab, a human anti-IL-6 monoclonal antibody, improves physical function in patients with active RA despite methotrexate therapy: results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study. [FRI0181]. EULAR 2012.
71. Hsu B, Sheng S, Weinblatt ME, et al. Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy. [OP0025]. EULAR2012.
72. Hsu B, Sheng S, Smolen JS, et al. Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy. [THU0100]. EULAR2012.
73. The long-term safety and efficacy of olokizumab (CDP6038) with active rheumatoid arthritis. ClinicalTrials.gov NCT01533714; (accessed 19 Apr 2015).
74. Efficacy and safety of olokizumab with rheumatoid arthritis with previously failed to anti-tumor necrosis factor (anti-TNF) therapy. ClinicalTrials.gov NCT01463059; (accessed 19 Apr 2015).
75. Open-label study to assess the safety and efficacy of CDP6038 in patients who completed RA0056. ClinicalTrials.gov. NCT01296711; (accessed 19 Apr 2015).
76. Phase IIB dose ranging study in subjects with moderate to severe rheumatoid arthritis. ClinicalTrials.gov NCT02015520; (accessed 19 Apr 2015).
77. A dose-range finding study for ALX-0061 combination therapy in subjects with rheumatoid arthritis. ClinicalTrials.gov NCT02309359; (accessed 19 Apr 2015).
78. A phase IIb study for ALX-0061 monotherapy in subjects with rheumatoid arthritis. ClinicalTrials.gov NCT02287922; (accessed 19 Apr 2015).
79. Safety and efficacy of AMG 827 in subjects with RA. ClinicalTrials. gov NCT01059448; (accessed 19 Apr 2015).
80. A study of mavrilimumab versus anti tumor necrosis factor in subjects with rheumatoid arthritis. ClinicalTrials.gov NCT01715896; (accessed 19 Apr 2015).
81. A long term safety study of mavrilimumab in adult subjects with rheumatoid arthritis. ClinicalTrials.gov NCT01712399; (accessed 19 Apr 2015).
82. Fischer JA, Hueber AJ, Wilson S, et al. Combined inhibition of tumor necrosis factor alpha and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheum 2015;67:51-62.